Prescriber's Corner

Idelalisib: The First-in-Class Phosphatidylinositol 3-Kinase Inhibitor for Relapsed CLL, SLL, and Indolent NHL

Nicholas Forcello, PharmD, BCPS, BCOP, and Nidhi Saraiya, PharmD

Hartford Hospital, Hartford, Connecticut

Authors' disclosures of potential conflicts of interest are found at the end of this article.

Nicholas Forcello, PharmD, BCPS, BCOP, Department of Pharmacy Services, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102. E-mail: nicholas.forcello@hhchealth.org


J Adv Pract Oncol 2014;5:455-459 | DOI: 10.6004/jadpro.2014.5.6.6 | © 2014 Harborside Press®


  



For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here
click me